Updated: City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field - Endpoints News

Source: Endpoints News · 2026-10-16T10:17:00+00:00

Updated: City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field Endpoints NewsCity goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq Fierce BiotechCity Therapeutics Announces Pricing of Upsized Initial Public Offering GlobeNewswireCTY FinvizForm S-1 City Therapeutics For: 15 October By Investing.com Investing.com Nigeria

BestAIBroker analysis

Finance-aware sentiment: slightly positive (+0.30 on a -1 to +1 scale).
Event classification: OTHER.
Market importance score: 24/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
Symbols referenced: WVE, ACHV, CAI, KZR, NDRA.

Read the original source